Sympathetic Innervation of the Heart and Cardiac Resynchronization Therapy(CRT) (PET-CRT)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00567645
: December 5, 2007
Last Update Posted
: May 13, 2016
University Medical Center Groningen
Information provided by (Responsible Party):
I.C. Van Gelder, University Medical Center Groningen
The purpose of this study is to assess whether baseline sympathetic innervation in patients with chronic heart failure (CHF) is predictive for response to cardiac resynchronization therapy (CRT). And to assess whether response to CRT coincides with restoration of regional sympathetic innervation.
sympathetic innervation in patients with chronic heart failure (CHF) [ Time Frame: 6 months ]
Secondary Outcome Measures
NYHA class Echocardiographic parameters: LVEDD, LVESD, LVEF, LVESV,IVMD, and septal to lateral delay Hospitalization for heart failure Maximal oxygen consumption NT pro-BNP changes [ Time Frame: 6 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 85 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
chronic heart failure patients with CRT
Indication for CRT
Stable optimal medication
Non ischemic cardiomyopathy
Age less then 18 years
Clinically relevant valvular heart disease or coronary artery disease
Acute or chronic infection
Untreated clinical hypo- or hyperthyroidism or < 3 months euthyroidism
Uncontrolled hypertension, defined as a systolic blood pressure > 160 mm Hg and/or a diastolic blood pressure > 95 mm Hg
A concurrent medical condition (i.e. alcohol or drug abuse or a severe progressive extra cardiac disease or M. Parkinson) or is unlikely to comply with the protocol
Participation to a previous protocol involving radioactivity in the past year